Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for the treatment of Gaucher disease Type 1. It is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase. It has an identical amino acid sequence to the naturally occurring enzyme.[1] It is manufactured by Shire plc.
The most common side effects include abdominal (belly) pain, headache, dizziness, bone pain, arthralgia (joint pain), back pain, infusion-related reactions, asthenia (weakness) or fatigue (tiredness), and pyrexia (fever) or increased body temperature.
Velaglucerase alfa was approved for medical use in the United States in February 2010,[2][3] and in the European Union in August 2010.[4]
Medical uses
Velaglucerase alfa is indicated for long-term enzyme-replacement therapy (ERT) in people with type-1 Gaucher disease.[4][5]
References
- Velaglucerase alfa in the treatment of Gaucher disease type 1 Clinical Investigation, February 2011^
- Shire Announces FDA Approval Of Vpriv (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease Medical News Today, 27 February 2010, retrieved 6 March 2010^
- Drug Approval Package: Vpriv (Velaglucerase alfa) NDA #022575 U.S. Food and Drug Administration (FDA), 24 February 2010, retrieved 17 February 2023^
- Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Vpriv EPAR European Medicines Agency (EMA), 17 September 2018, retrieved 13 August 2020^
- Vpriv- velaglucerase alfa injection, powder, lyophilized, for solution DailyMed, 18 June 2020, retrieved 13 August 2020^